Lv4
580 积分 2022-08-16 加入
Abstract PO3-18-06: First-in-human phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with hormone receptor positive (HR+) HER2- advanced/metastatic breast cancer (ABC) who progressed on prior CDK4/6 inhibitors (CDK4/6i)
20天前
已完结
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
25天前
已完结
Tumor-Agnostic Approvals: Insights and Practical Considerations
3个月前
已完结
Structural Biology of the Tumor Suppressor p53
3个月前
已完结
The IARC TP53 database: new online mutation analysis and recommendations to users
3个月前
已完结
[Guidelines for clinical diagnosis and treatment of advanced triple negative breast cancer in China（2024 edition）]
3个月前
已完结
Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020
3个月前
已完结
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
3个月前
已完结
Phenylalanine hydroxylase deficiency: diagnosis and management guideline
4个月前
已完结
Correction: Corrigendum: Phenylalanine hydroxylase deficiency: diagnosis and management guideline
4个月前
已完结
皖公网安备34019202002308
